Citations for
1SLC18A2
Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease.
Sala G, Brighina L, Saracchi E, Fermi S, Riva C, Carrozza V, Pirovano M, Ferrarese C.
J Neural Transm 117(9):1093-8. Epub 2010 Jul 28.PMID: 20665056 2010
2SLC18A2
Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways.
Onoa B, Li H, Gagnon-Bartsch JA, Elias LA, Edwards RH.
J Neurosci 30(23):7917-27.PMID: 20534840 2010
3SLC18A2
High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.
Lin Z, Zhao Y, Chung CY, Zhou Y, Xiong N, Glatt CE, Isacson O.
FASEB J 24(7):2191-200. Epub 2010 Feb 24.PMID: 20181938 2010
4SLC18A2
Increased expression of VMAT2 in dopaminergic neurons during nicotine withdrawal.
Duchemin AM, Zhang H, Neff NH, Hadjiconstantinou M.
Neurosci Lett 467(2):182-6. Epub 2009 Oct 14.PMID: 19835933 2009
5HSPA8, SLC18A2
The molecular chaperone Hsc70 interacts with the vesicular monoamine transporter-2.
Requena DF, Parra LA, Baust TB, Quiroz M, Leak RK, Garcia-Olivares J, Torres GE.
J Neurochem 110(2):581-94. Epub 2009 Apr 30.PMID: 19457116 2009
6SLC18A2
Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Yasumoto S, Tamura K, Karasawa J, Hasegawa R, Ikeda K, Yamamoto T, Yamamoto H.
Neurosci Lett 454(3):229-32. Epub 2009 Mar 18.PMID: 19429089 2009
7SLC18A2
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD, Wild PJ, Mortezavi A, Adolf K, Tørring N, Heebøll S, Ulhøi BP, Ottosen P, Sulser T, Hermanns T, Moch H, Borre M, Ørntoft TF, Dyrskjøt L.
Clin Cancer Res 15(4):1400-10.PMID: 19228741 2009
8SLC18A2
Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas.
Saisho Y, Harris PE, Butler AE, Galasso R, Gurlo T, Rizza RA, Butler PC.
J Mol Histol 39(5):543-51. Epub 2008 Sep 13.PMID: 18791800 2008
9SLC18A2
Expression and function of the rat vesicular monoamine transporter 2.
Adam Y, Edwards RH, Schuldiner S.
Am J Physiol Cell Physiol 294(4):C1004-11. Epub 2008 Feb 20.PMID: 18287335 2008
10SLC18A2
Identification of two risk haplotypes for schizophrenia and bipolar disorder in the synaptic vesicle monoamine transporter gene (SVMT).
Gutierrez B, Rosa A, Papiol S, Arrufat FJ, Catalan R, Salgado P, Peralta V, Cuesta MJ, Fananas L.
Am J Med Genet B Neuropsychiatr Genet 144(4):502-7. 2007
11SLC18A2
Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.
Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B.
Hum Mol Genet 15(2):299-305. Epub 2005 Dec 8. 2006
12SLC18A2
SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism.
Lin Z, Walther D, Yu XY, Li S, Drgon T, Uhl GR.
Hum Mol Genet 14(10):1393-404. Epub 2005 Apr 13. 2005
13SLC18A2
Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond.
Thiriot DS, Sievert MK, Ruoho AE.
Biochemistry 41(20):6346-53. 2002
14SLC18A2
The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins.
Uhl GR, Li S, Takahashi N, Itokawa K, Lin Z, Hazama M, Sora I.
FASEB J 14(15):2459-65. Review. 2000
15SLC18A1, SLC18A2
Chromosomal localization of the human vesicular amine transporter genes.
Peter D, et al.
Genomics 18 : 720-723. 1993
16SLC18A2
A human synaptic vesicle monoamine transporter cDNA predicts posttransnational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs.
Surratt CK, et al.
FEBS Lett 318 : 325-330. 1993
17SLC18A1, SLC18A2
Expression cloning of a reserpine-sensitive vesicular monoamine transporter.
Erickson JD, et al.
Proc Natl Acad Sci U S A 89 : 10993-10997. 1992